Paradigm Biopharmaceuticals has suffered a setback after an independent monitoring board found that its Phase 3 knee ...

The final visit took place in the United States this week. The company told investors that topline results from the XanaMIA ...

Perth company Patrys has started in-human testing of its intravenous version of the antipsychotic quetiapine. The first ...

Prescient Therapeutics has raised $6 million from shareholders and investors. The money will fund its lead cancer drug ...

BCAL Diagnostics has started a phased rollout of Avantect Multi-Cancer in Sydney and Melbourne and plans to expand nationally ...

Melbourne kidney disease drug developer Dimerix has drawn $17 million from a $34 million loan facility as its lead candidate ...

Seven Australian startups will share $15.6 million to speed up the development of new treatments, diagnostic tools and technologies for dementia and cognitive decline.

BCAL Diagnostics has started a phased rollout of Avantect Multi-Cancer in Sydney and Melbourne and plans to expand nationally later.